Share price of this micro-cap stock moved up by nearly 6.48 percent on BSE to Rs. 60.30 in the morning trading session of Monday, compared to its previous close of Rs. 56.63, after the successful completion of USFDA inspection.
With a market capitalisation of Rs. 93.02 crore, at 12:11 p.m. the shares of Jeevan Scientific Technology Ltd. (JTSL) were trading at Rs. 59.90, up by 5.77 percent.
In the last one year, the company has delivered positive returns of nearly 17.46 percent. However, it has delivered around 6.95 of negative returns in the last six months as well as 3.25 percent of negative returns, so far in 2024.
According to the BSE filings, the United States Food and Drug Administration (USFDA) conducted an inspection of the company’s Bioanalytical Facility, at Manikonda, Hyderabad., to review the BA/BE studies as well as the operations, systems and procedures.
The inspector concluded the inspection by stating that the entire JSTL team is well trained, knowledgeable and experienced with International Regulatory requirements and Good practices, that they work within an adequately designed infrastructure, and that the organisation complies with all applicable regulations.
In terms of financials, the revenue from operations of the company increased by 25.68 percent QoQ from Rs. 8.06 crore in Q2 FY23-24 to Rs. 10.13 crore in Q3 FY23-24.
The quarterly net profit of the company is Rs. -0.49 crore in Q3 FY23-24 which is a growth of 19.67 percent on a quarter-on-quarter basis from Rs. -0.61 crore in Q2 FY23-24.
As of December 2023, the Promoters’ holdings remain unchanged at 39.48 percent, as well as the Public holdings remain the same at 61.51 percent.
Established in the year 1999, Jeevan Scientific Technology Limited was incorporated as Jeevan Softech Pvt Ltd.
The company is a clinical research organisation with a focus on Pharmacovigilance and clinical trial business (CT).
Written by Shivani Singh
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Dailyraven Technologies or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
